RecruitingPhase 1NCT07524348

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors

Sponsor

Samsung Bioepis Co., Ltd.

Enrollment

149 participants

Start Date

Mar 23, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called E303 for people with advanced solid tumors. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.